International Pediatric Peritoneal Biobank for Kidney Failure

This observational study is collecting tissue samples to understand how the lining of the abdomen (peritoneal membrane) changes in children and adults with kidney failure who are on peritoneal dialysis (PD). Researchers are interested in how the membrane transforms over time, leading to issues like fibrosis (scarring) and vasculopathy (blood vessel disease), which can cause PD to fail. They are also studying people with normal kidney function who are having abdominal surgery. The goal is to understand these changes, especially in children where aging or diabetes are not factors. The study plans to enroll 500 participants aged 1 day to 90 years.

Study design: This is an observational study with a planned enrollment of 500 participants. It is not testing a new treatment, but rather observing changes in the body.
What's involved: You would have two small tissue samples taken from the lining of your abdomen and three from the omentum (a fatty tissue in the abdomen) during surgery.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, peritoneal vasculopathy, will be measured at two years (mean PD treatment time).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

International (Pediatric) Peritoneal Biobank

Recruiting

Not specifiedAges 1–90Observational

Heidelberg University

~500 participants

Updated 2026-04-30 on ClinicalTrials.gov

What's tested:biopsy sampling

At a glance

Recruiting sites

17 of 26 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Peritoneal vasculopathy (lumen vessel ratio)

Measured over Two years (Mean PD treatment time)

Conditions

Kidney Failure, Chronic

Peritoneal Dialysis Complication

Transplantation

Healthy

Where it's being run

26 sites across 18 states

Germany5

Italy3

France2

Turkey (Türkiye)2

Alabama1

Missouri1

Pennsylvania1

Austria1

Study leadership

Claus P Schmitt, MD · PRINCIPAL_INVESTIGATOR · University of Heidelberg, Center for Pediatric and Adolescent Medicine

Who to contact

Claus P Schmitt, Prof

[email protected]

+49 6221 56 · ext. 39313

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age 0 to 90 years

CKD 5D, peritoneal dialysis and

Patients with normal renal function and elective abdominal surgery due to limited abdominal pathology (such as hernia repair, gallstones….)

Patients post PD and post Tx

Oral and written consent

Ability to consent of the adult patient and of the parents and legal guardian of patients not yet of legal age, respectively

Exclusion

Abdominal adhesions, malformation and inflammation beyond PD induced changes

Patients with disseminated tumour disease

Patients with critical heart failure and other medical conditions, where the additional procedure may confer an increased increase risk

Pregnancy

Preterm babies (below 37 weeks of gestational age)

Serum hemoglobin \< 10 g/dl in newborns and \< 8 g/dl in children and adults

What this trial measures

Peritoneal vasculopathy (lumen vessel ratio)Two years (Mean PD treatment time)
Digital quantification of degree of vasculopathy, i.e the lumen vessel ratio. Healthy children have a L/V ratio of about 0.7. lower values represent vasculopathy with lumen narrowing, 0 is complete obliteration of the vessel. This measurements will be accompanied by molecular analysis of pathomechanisms (including omics Technology)

Trialytics